DK0904392T3 - Retrovirale vektorer - Google Patents

Retrovirale vektorer

Info

Publication number
DK0904392T3
DK0904392T3 DK97909436T DK97909436T DK0904392T3 DK 0904392 T3 DK0904392 T3 DK 0904392T3 DK 97909436 T DK97909436 T DK 97909436T DK 97909436 T DK97909436 T DK 97909436T DK 0904392 T3 DK0904392 T3 DK 0904392T3
Authority
DK
Denmark
Prior art keywords
vector particle
vector
retroviral vectors
lentivirus
infecting
Prior art date
Application number
DK97909436T
Other languages
Danish (da)
English (en)
Inventor
Kyriacos Mitrophanous
Narry Kim
Alan John Kingsman
Susan Mary Kingsman
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621680.9A external-priority patent/GB9621680D0/en
Priority claimed from GBGB9624457.9A external-priority patent/GB9624457D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of DK0904392T3 publication Critical patent/DK0904392T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97909436T 1996-10-17 1997-10-17 Retrovirale vektorer DK0904392T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9621680.9A GB9621680D0 (en) 1996-10-17 1996-10-17 Lentiviral vectors
GBGB9624457.9A GB9624457D0 (en) 1996-11-25 1996-11-25 Retroviral vectors
PCT/GB1997/002857 WO1998017815A1 (en) 1996-10-17 1997-10-17 Retroviral vectors

Publications (1)

Publication Number Publication Date
DK0904392T3 true DK0904392T3 (da) 2001-04-30

Family

ID=26310246

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97909436T DK0904392T3 (da) 1996-10-17 1997-10-17 Retrovirale vektorer

Country Status (23)

Country Link
US (2) US6312682B1 (no)
EP (2) EP1041152A1 (no)
JP (2) JP4418536B2 (no)
KR (1) KR20000049251A (no)
CN (1) CN1195863C (no)
AT (1) ATE198910T1 (no)
AU (1) AU725143B2 (no)
BG (1) BG103397A (no)
CA (1) CA2267636A1 (no)
CZ (1) CZ137399A3 (no)
DE (1) DE69703974T2 (no)
DK (1) DK0904392T3 (no)
ES (1) ES2153654T3 (no)
GB (1) GB2325003B (no)
GR (1) GR3035600T3 (no)
HK (2) HK1014993A1 (no)
HU (1) HUP0000421A2 (no)
IL (1) IL129017A0 (no)
NO (1) NO991781L (no)
NZ (1) NZ334860A (no)
PL (1) PL332875A1 (no)
PT (1) PT904392E (no)
WO (1) WO1998017815A1 (no)

Families Citing this family (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1041152A1 (en) * 1996-10-17 2000-10-04 Oxford Biomedica (UK) Limited Retroviral vectors
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US7198784B2 (en) * 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
AU752753B2 (en) * 1997-04-09 2002-09-26 Lung-Ji Chang Animal model for evaluation of vaccines
AU741747B2 (en) 1997-05-13 2001-12-06 University Of North Carolina At Chapel Hill, The Lentivirus-based gene transfer vectors
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
DK1895010T3 (da) * 1997-12-22 2011-11-21 Oxford Biomedica Ltd Vektorer baseret på virus for infektiøs hesteanæmi (eiav)
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
ES2291025T3 (es) 1998-05-13 2008-02-16 Genetix Pharmaceuticals Inc. Celulas lentivirales de empaquetamiento.
WO1999067400A1 (en) 1998-06-24 1999-12-29 Musc Foundation For Research Development Tissue-specific and target rna-specific ribozymes
US6958226B1 (en) 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
GB9906177D0 (en) * 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
IL146144A0 (en) * 1999-04-29 2002-07-25 Cell Genesys Inc Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2001030847A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
CN1321182C (zh) * 1999-12-30 2007-06-13 卫生部艾滋病预防与控制中心 马传染性贫血病毒代表毒株的全基因克隆及其应用
EP1702983A3 (en) 2000-04-13 2007-01-10 Medical University of South Carolina Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof
ES2276788T3 (es) 2000-05-10 2007-07-01 Sanofi Pasteur Limited Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones.
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
GB0024550D0 (no) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
US20030039636A1 (en) * 2001-05-01 2003-02-27 Genetix Pharmaceuticals, Inc. Novel self-inactivating (SIN) lentiviral vectors
CA2451173C (en) 2001-06-29 2012-12-18 Sloan Kettering Institute For Cancer Research Vector encoding human globlin gene and use thereof in treatment of hemoglobinopathies
IL160132A0 (en) 2001-08-02 2004-06-20 Inst Clayton De La Rech Methods and compositions relating to improved lentiviral vector production systems
CA2915676C (en) * 2001-10-02 2017-06-06 Institut Clayton De La Recherche Restricted expression lentiviral vectors
EP1504108B1 (en) 2002-02-01 2013-04-17 Oxford Biomedica (UK) Limited Lentiviral vector
GB0221778D0 (en) * 2002-09-19 2002-10-30 Molmed Spa Conjugate
CA2506798C (en) * 2002-11-22 2013-01-22 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
GB0325379D0 (en) * 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
ES2417019T3 (es) 2003-11-13 2013-08-05 University Of Georgia Research Foundation, Inc. Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa
CA2556911C (en) 2004-02-19 2013-07-30 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
CA2561714A1 (en) * 2004-04-08 2005-10-27 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
WO2005100393A1 (en) * 2004-04-08 2005-10-27 Sangamo Biosciences, Inc. Methods and compositions for modulating cardiac contractility
WO2005118809A2 (en) * 2004-04-29 2005-12-15 The University Of North Carolina At Chapel Hill Methods and compositions for enhancing cell adhesion properties
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
PL1881845T3 (pl) 2005-04-25 2010-08-31 Merial Ltd Szczepionki przeciwko wirusowi Nipah
US20060292159A1 (en) * 2005-06-08 2006-12-28 Ranscht Barbara E Methods for the inhibition of neovascularization and cancer metastasis
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP2186823A1 (en) 2005-11-14 2010-05-19 Merial Limited Gene therapy for renal failure
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
WO2008134879A1 (en) 2007-05-04 2008-11-13 University Health Network Il-12 immunotherapy for cancer
EP2348052A3 (en) 2007-09-17 2011-10-26 The Regents of The University of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
US8617534B2 (en) 2007-11-16 2013-12-31 San Diego State University (Sdsu) Foundation Compositions and method for manipulating PIM-1 activity in circulatory system cells
US20110015239A1 (en) * 2007-12-14 2011-01-20 The Regents Of The University Of California Inhibitors of calcium-activated chloride channels
WO2009153563A1 (en) 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
CA2757030C (en) 2009-04-03 2019-01-15 Merial Limited Vectors comprising newcastle disease viruses and compositions thereof
EP2575894B1 (en) 2010-05-28 2015-02-25 Oxford Biomedica (UK) Ltd Delivery of lentiviral vectors to the brain
WO2012030720A1 (en) 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
WO2012145577A1 (en) 2011-04-20 2012-10-26 Merial Limited Adjuvanted rabies vaccine with improved viscosity profile
KR102007444B1 (ko) 2011-04-25 2019-08-06 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물
EP2714077B1 (en) 2011-06-01 2018-02-28 Merial, Inc. Needle-free administration of prrsv vaccines
JP6041361B2 (ja) 2011-08-12 2016-12-07 メリアル インコーポレイテッド 生物学的製品、特にはワクチンの真空保存
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
HRP20231183T1 (hr) 2013-02-15 2024-01-05 Bioverativ Therapeutics Inc. Optimizirani gen faktora viii
US9556419B2 (en) 2013-03-12 2017-01-31 Merial Inc. Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
MY177482A (en) * 2013-03-13 2020-09-16 Zhong Li Microvesicle and method for producing the same
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
AU2014338555B2 (en) 2013-10-24 2019-10-10 Fondazione Telethon Method
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
GB201407322D0 (en) 2014-04-25 2014-06-11 Ospedale San Raffaele Gene therapy
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
EP3215188A1 (en) 2014-11-03 2017-09-13 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
US20180271891A1 (en) 2015-03-11 2018-09-27 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
KR20180010229A (ko) 2015-05-20 2018-01-30 더 브로드 인스티튜트, 인코퍼레이티드 공유 신생항원
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
PL3313864T3 (pl) 2015-06-23 2022-01-03 Boehringer Ingelheim Animal Health USA Inc. Rekombinowane wektory wirusowe zawierające drugorzędne białko prrsv oraz sposoby ich wytwarzania i zastosowania
EP3380620A1 (en) 2015-11-23 2018-10-03 Novartis AG Optimized lentiviral transfer vectors and uses thereof
WO2017095823A1 (en) 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
SI3411478T1 (sl) 2016-02-01 2022-10-28 Bioverativ Therapeutics Inc. Optimirani geni dejavnika VIII
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US20190225956A1 (en) 2016-05-10 2019-07-25 United States Government As Represented By The Department Of Veterans Affairs Lentiviral delivery of crispr/cas constructs that cleave genes essential for hiv-1 infection and replication
JP6982001B2 (ja) * 2016-05-13 2021-12-17 フラッシュ セラピューティクス ゲノム工学システムのカプシド形成のための粒子
MX2019004259A (es) 2016-10-12 2019-09-27 Bioverativ Usa Inc Anticuerpos anti-c1s y metodos de uso de los mismos.
WO2018083538A1 (en) 2016-11-07 2018-05-11 Neuracle Scienc3 Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
WO2018089807A2 (en) 2016-11-11 2018-05-17 The Regents Of The University Of California Anti-cd46 antibodies and methods of use
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11965892B2 (en) 2017-02-12 2024-04-23 Biontech Us Inc. HLA-based methods and compositions and uses thereof
CA3056542A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
WO2019003159A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF FIBROSIS
EP3645044A4 (en) 2017-06-27 2021-04-28 Neuracle Science Co., Ltd USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA
KR102574549B1 (ko) 2017-06-27 2023-09-07 주식회사 뉴라클사이언스 항-fam19a5 항체 및 이의 용도
KR20230142819A (ko) 2017-06-27 2023-10-11 주식회사 뉴라클사이언스 암 치료를 위한 항-fam19a5 항체의 용도
WO2019068854A1 (en) 2017-10-06 2019-04-11 Ospedale San Raffaele S.R.L. GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
US11192944B2 (en) 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity
EP3696272A1 (en) 2017-12-22 2020-08-19 Oxford BioMedica (UK) Limited Retroviral vector
SG11202007114VA (en) 2018-02-01 2020-08-28 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor viii
WO2019207513A1 (en) 2018-04-24 2019-10-31 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
AU2019265888A1 (en) 2018-05-10 2020-11-26 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
CA3099497A1 (en) 2018-05-15 2019-11-21 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
JP2021529184A (ja) 2018-06-25 2021-10-28 オスペダーレ サン ラファエレ エス．アール．エル 遺伝子治療
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
EP3820509A1 (en) 2018-07-09 2021-05-19 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
EP3864146A1 (en) 2018-10-11 2021-08-18 Ospedale San Raffaele S.r.l. Selection by means of artificial transactivators
SG11202105079QA (en) 2018-11-14 2021-06-29 Flagship Pioneering Innovations V Inc Fusosome compositions for cns delivery
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
CA3120282A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
CA3119341A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
US20220017921A1 (en) * 2018-12-04 2022-01-20 The Broad Institute, Inc. Improved vector systems for cas protein and sgrna delivery, and uses therefor
JP2022514465A (ja) 2018-12-06 2022-02-14 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子を発現するレンチウイルスベクターの使用
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
BR112021012278A2 (pt) 2018-12-21 2021-12-14 Biontech Us Inc Método e sistema para a preparação de células hla de classe ii-específica de epitopes e de síntese de cd4 + t
US20220175962A1 (en) 2019-03-10 2022-06-09 Sio Gene Therapies Inc. Gene therapy compositions and methods for treating parkinson's disease
GB201905244D0 (en) 2019-04-12 2019-05-29 Ospedale San Raffaele Method for analysisng insertion sites
GB201905301D0 (en) 2019-04-15 2019-05-29 Ospedale San Raffaele Srl Gene therapy
GB201907493D0 (en) 2019-05-28 2019-07-10 Ospedale San Raffaele Agents and methods for treating viral infections
AU2020341454A1 (en) 2019-09-03 2022-03-10 Sana Biotechnology, Inc. CD24-associated particles and related methods and uses thereof
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
CN114667161A (zh) 2019-11-12 2022-06-24 牛津生物医学（英国）有限公司 生产系统
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
EP4093752A2 (en) 2020-01-22 2022-11-30 Outpace Bio, Inc. Chimeric polypeptides
WO2021151001A1 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
WO2021160993A1 (en) 2020-02-13 2021-08-19 Oxford Biomedica (Uk) Limited Production of lentiviral vectors
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
EP4118217A1 (en) 2020-03-13 2023-01-18 Oxford BioMedica (UK) Limited Lentiviral vectors
CN116096866A (zh) 2020-03-31 2023-05-09 萨那生物科技公司 靶向脂质颗粒及其组合物和用途
AU2021264465A1 (en) 2020-04-27 2022-12-15 University Of Iowa Research Foundation Compositions and methods for the treatment of cystic fibrosis
GB202007106D0 (en) 2020-05-14 2020-07-01 Ucl Business Plc Cyclosporine analogues
GB202007169D0 (en) 2020-05-14 2020-07-01 Ospedale San Raffaele Srl Epidermal growth factor receptor
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
TW202208619A (zh) 2020-06-24 2022-03-01 美商百歐維拉提夫治療公司 用於純化病毒載體之方法
GB202010009D0 (en) 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
IL300528A (en) 2020-08-07 2023-04-01 Fortis Therapeutics Inc Immune conjugates targeting cd46 and methods of using them
US20230303665A1 (en) 2020-08-28 2023-09-28 Sana Biotechnology, Inc. Modified anti-viral binding agents
US20230365996A1 (en) 2020-10-12 2023-11-16 Ospedale San Raffaele S.R.L. Replacement of rag1 for use in therapy
EP4232566A1 (en) 2020-10-22 2023-08-30 Lyell Immunopharma, Inc. Chimeric activation receptors
KR20230098201A (ko) 2020-10-26 2023-07-03 네오이뮨텍, 인코퍼레이티드 줄기 세포 동원의 유도 방법
US20240101629A1 (en) 2020-11-02 2024-03-28 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
AU2021376396A1 (en) 2020-11-05 2023-06-08 Neoimmunetech, Inc. Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
GB202018657D0 (en) 2020-11-26 2021-01-13 Ospedale San Raffaele Srl Agents and methods for increasing liver immune response
GB202019108D0 (en) 2020-12-03 2021-01-20 Ospedale San Raffaele Srl Vector
WO2022132596A2 (en) 2020-12-14 2022-06-23 Biontech Us Inc. Tissue-specific antigens for cancer immunotherapy
JP2024501971A (ja) 2020-12-31 2024-01-17 サナ バイオテクノロジー，インコーポレイテッド Ｃａｒ－ｔ活性を調節するための方法及び組成物
CA3204161A1 (en) 2021-01-11 2022-07-14 Jagesh Vijaykumar SHAH Use of cd8-targeted viral vectors
CA3207426A1 (en) 2021-02-15 2022-08-18 Vania Broccoli Epigenetic silencing for treatment of cancer
GB202103470D0 (en) 2021-03-12 2021-04-28 Univ Bristol Promoter
WO2022232191A1 (en) 2021-04-26 2022-11-03 Csl Behring L.L.C. Lentiviral vectors useful for the treatment of disease
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
CN117642420A (zh) 2021-05-28 2024-03-01 萨那生物科技公司 含有截短的狒狒内源性逆转录病毒(BaEV)包膜糖蛋白的脂质颗粒及相关方法和用途
WO2022256437A1 (en) 2021-06-02 2022-12-08 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
KR20240046319A (ko) 2021-07-14 2024-04-08 사나 바이오테크놀로지, 인크. 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
WO2023015217A1 (en) 2021-08-04 2023-02-09 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
IL311725A (en) 2021-09-30 2024-05-01 Bioverativ Therapeutics Inc Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
CA3234828A1 (en) 2021-10-12 2023-04-20 Anna Villa Polynucleotides useful for correcting mutations in the rag1 gene
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114972D0 (en) 2021-10-19 2021-12-01 Ospedale San Raffaele Srl Gene therapy
WO2023077107A1 (en) 2021-10-29 2023-05-04 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023115039A2 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023115041A1 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
EP4209511A1 (en) 2022-01-05 2023-07-12 Gyala Therapeutics Sociedad Limitada Anti-cd84 antibodies amd chimeric antigen receptors
WO2023131657A1 (en) 2022-01-05 2023-07-13 Gyala Therapeutics Sociedad Limitada Anti-cd84 antibodies and chimeric antigen receptors
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
GB202204272D0 (en) 2022-03-25 2022-05-11 Ucl Business Ltd Method for engineering innate-like lymphocytes
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023198828A1 (en) 2022-04-13 2023-10-19 Universitat Autònoma De Barcelona Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
GB202209098D0 (en) 2022-06-21 2022-08-10 Ucl Business Ltd Cyclosporine analogues
WO2024003578A1 (en) 2022-07-01 2024-01-04 The University Of Bristol Vector comprising a sequence encoding an anti-tnf antibody and an inflammation-inducible promoter
EP4303226A1 (en) 2022-07-08 2024-01-10 Ospedale San Raffaele S.r.l. Transgene cassettes and epigenetic silencers for the treatment of disorders
WO2024008950A1 (en) 2022-07-08 2024-01-11 Ospedale San Raffaele S.R.L. Transgene cassettes
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
WO2024033544A1 (en) 2022-08-12 2024-02-15 Ospedale San Raffaele S.R.L. Deglycosylation of native glycoproteins expressed on a tumor cell surface
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024100294A1 (en) 2022-11-11 2024-05-16 Ospedale San Raffaele S.R.L. Cdh17 car

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0213894A3 (en) * 1985-08-23 1987-10-21 Advanced Genetics Research Institute Defective viral particle vaccines and methods for their use
EP0536234A4 (en) * 1990-06-20 1993-09-15 Dana Farber Cancer Institute Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof
JPH06510181A (ja) * 1991-05-29 1994-11-17 アメリカ合衆国 Ｒｎａプロセシングの調節機能を備えた真核細胞発現ベクター
US5981505A (en) * 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
DE69430646T2 (de) * 1993-02-17 2003-01-02 Wisconsin Alumni Res Found Retroviren vom Typ "more-complex", die LTR von gemischtem Typ enthalten und deren Anwendungen
AU2419595A (en) * 1994-05-10 1995-11-29 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same
US6326007B1 (en) * 1995-07-20 2001-12-04 The Regents Of The University Of California Attenuated lentivirus vectors expressing interferon
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU7435296A (en) * 1995-10-16 1997-05-07 Dana-Farber Cancer Institute Novel expression vectors and methods of use
EP1041152A1 (en) * 1996-10-17 2000-10-04 Oxford Biomedica (UK) Limited Retroviral vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors

Also Published As

Publication number Publication date
JP2009291205A (ja) 2009-12-17
JP4418536B2 (ja) 2010-02-17
CA2267636A1 (en) 1998-04-30
US6669936B2 (en) 2003-12-30
HK1016651A1 (en) 1999-11-05
US6312682B1 (en) 2001-11-06
ATE198910T1 (de) 2001-02-15
AU4712297A (en) 1998-05-15
HK1014993A1 (en) 1999-10-08
EP0904392B1 (en) 2001-01-24
IL129017A0 (en) 2000-02-17
EP1041152A1 (en) 2000-10-04
CN1234836A (zh) 1999-11-10
JP4855504B2 (ja) 2012-01-18
CZ137399A3 (cs) 1999-07-14
ES2153654T3 (es) 2001-03-01
BG103397A (en) 2000-07-31
US20020034502A1 (en) 2002-03-21
HUP0000421A2 (hu) 2000-06-28
AU725143B2 (en) 2000-10-05
NO991781D0 (no) 1999-04-14
NO991781L (no) 1999-06-17
CN1195863C (zh) 2005-04-06
PT904392E (pt) 2001-06-29
KR20000049251A (ko) 2000-07-25
DE69703974T2 (de) 2001-07-19
GB2325003B (en) 2000-05-10
EP0904392A1 (en) 1999-03-31
GB9815778D0 (en) 1998-09-16
GR3035600T3 (en) 2001-06-29
WO1998017815A1 (en) 1998-04-30
PL332875A1 (en) 1999-10-25
GB2325003A (en) 1998-11-11
DE69703974D1 (de) 2001-03-01
NZ334860A (en) 2001-02-23
JP2001502539A (ja) 2001-02-27

Similar Documents

Publication Publication Date Title
DE69703974T2 (de) Retrovirale vektoren
ATE520783T1 (de) Lentivirale vektoren
CY1106513T1 (el) Λεντινοϊικο τριπλο dna και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dna
BR8605053A (pt) Processos para a preparacao de um polipeptidio,para a preparacao de um gene sintetico,para a preparacao de um vetor de expressao,para a preparacao de um transformante bacteriano,para a determinacao de anticorpos e de virus,para a preparacao de vacina,vacinas,anticorpos,polipeptidos,gene,vetor,transformante,kit de teste
ATE312178T1 (de) Infektiöse pseudovirale papillomavirus partikel
DE69637677D1 (de) Transfer system basierend auf einem fusionsprotein und seine anwendungen.
DE60044754D1 (de) Trans-lentivirales Vektor System
ATE363070T1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
AU630861B2 (en) Recombinant hiv-2 polypeptides
PT880594E (pt) Vector retroviral e sua utilizacao em terapia genica
PT975783E (pt) "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas"
DE69715672D1 (de) Reporter-zellinie zum nachweis des cytomegalovirus und zur identifizierung von modulatoren der viralen genexpression
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
DK631387D0 (da) Virusvektor
ATE393819T1 (de) Verwendungen von immortalisierten, homozygoten stat1-defizienten säugerzelllinien
Lin et al. Retrovirus-Mediated Gene Transduction of SupT1 Cells